Market Size Estimation:
Top-down and bottom-up approaches were used to validate the size of the transdermal drug delivery systems market and estimate the size of other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
# The key players in the industry and markets have been identified through extensive secondary research.
# The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Data Triangulation:
After arriving at the overall market size using the market size estimation processes as explained above the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both, the demand and supply sides.
Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203190114
Expected Revenue Growth During Forecast:
The transdermal drug delivery systems market is expected to reach USD 7.1 billion by 2023 from an estimated USD 5.7 billion in 2018, at a CAGR of 4.5% during the forecast period. The growth of this market is primarily driven by factors such as the increase in the prevalence of chronic diseases and technological advancements in transdermal drug delivery systems.
Recent Developments:
# In January 2018, Hisamitsu Pharmaceutical (Japan) launched ALLESAGA TAPE in the Japanese market.
# In July 2018, UCB (Belgium) received the Import Drug License (IDL) for its transdermal rotigotine patch—NEUPRO from the China Food and Drug Administration (CFDA).
# In August 2018, Luye Pharma (China) signed an agreement with Bayer AG (Switzerland) to acquire the global rights to the Apleek contraceptive transdermal patch.
The pain management segment is expected to account for the largest share of the market in 2018
On the basis of application, the market is segmented into pain management, central nervous system disorders, hormonal applications, cardiovascular diseases, and other applications (smoking cessation, motion sickness, and overactive bladder treatment). In 2018, the pain management segment is expected to account for the largest share of the transdermal drug delivery systems market. Growth in this market is largely driven by the high burden of chronic pain worldwide and the growing availability of transdermal products for pain management.
Geographical Growth Segmentation:
North America to dominate the transdermal drug delivery systems market in 2018
North America is expected to dominate the transdermal drug delivery systems market in 2018. The large share of the North American transdermal drug delivery systems market can primarily be attributed to the rising prevalence of targeted diseases (such as chronic pain, central nervous system disorders, and cardiovascular diseases) in the region, the increasing use of contraceptives, and the increasing number of research activities related to transdermal drug delivery systems.
Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=203190114
Global Leaders:
The key players in the transdermal drug delivery systems market are Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), GlaxoSmithKline (UK), Boehringer Ingelheim (Germany), Johnson & Johnson (US), Endo International (Ireland), and Purdue Pharma (US).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
Transdermal Drug Delivery Systems Market worth $7.1 billion by 2023
Transdermal Drug Delivery Systems: IntroductionTransdermal is a route of administration, wherein drugs are administered through the skin to achieve systemic distributionRecent advancements in transdermal route of administration such as ultrasound waves, laser, and microneedle patches for efficient penetration of the dermis layer of the skin drive the global transdermal drug delivery systems marketRequest Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=158 Key Drivers and Restraints of Global Transdermal Drug Delivery Systems MarketDemand for novel techniques with low dose and less dosing frequency of drugs is increasing rapidly.
Patients being discharged from health care services such as hospitals and clinics still need observation.
Hence, both professional caregivers and laypersons are using several types of equipment or devices, some of these composite, in non-institutional settings to control personal health, support others, or take support of health organization.
These equipment offer support in several health conditions such as chronic and acute diseases and help in prevention of diseases.Demand for automated drug delivery systems has increased.
For instance, Logiq wireless solutions is a remotely controlled transdermal drug delivery device.
These factors are projected to drive the global transdermal drug delivery systems market.Request COVID Analysis on Transdermal Drug Delivery Systems Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=158 Diabetes Application Segment to Lead Global MarketThe global transdermal drug delivery systems market can be segmented based on application, end-user, and regionIn terms of application, the global transdermal drug delivery systems market can be divided into infectious diseases, oncology, ophthalmology, urology, diabetes, CNS, and others.
The Global Transdermal (Percutaneous) Drug Delivery Systems Market Held A Market Value Of USD 5,400.2 Million In 2017 And Is Projected To Grow At A CAGR Of 4.6% Over The Forecast Period.Transdermal drug delivery system (TDDS) delivers drugs into systemic circulation into the skin through the skin at a predetermined rate with minimal inter and intrapatient variation.
For instance, as per the data published by the World Health Organization (WHO), in 2001, chronic diseases accounted for around 60.0% of the 56.5 million total reported deaths in the world and almost 46% of the global burden of disease.
By the end of 2020, chronic diseases are anticipated to contribute for nearly three-quarters of all deaths worldwide, and that 75% of deaths due to stroke, 71% of deaths due to ischemic heart disease (IHD), and 70% of deaths due to diabetes will occur in developing countries.Free sample report @ https://www.marketresearchfuture.com/sample_request/7545Key PlayersSome of the foremost players in the global transdermal (percutaneous) drug delivery systems market are Mylan N.V., Hisamitsu Pharmaceutical Co., Inc., Novartis International AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Endo Pharmaceuticals Inc., UCB S.A., Pfizer Inc., Allergan plc, Actelion Pharmaceuticals Ltd, and Noven Pharmaceuticals, Inc.SegmentationThe global transdermal (percutaneous) drug delivery systems market has been segmented into product, technology, application, and region.By product, the market has been segmented into transdermal patches and transdermal semisolids.
The transdermal semisolids segment is additionally divided into gels, ointments, and sprays.On the basis of technology, the market has been divided into electric current, iontophoresis, electroporation, ultrasound, microporation, thermal, and others.Based on application, the market has been categorized into pain management, cardiovascular diseases, hormone replacement therapy, central nervous system disorders, smoking cessation, contraception, and others.Few of the technological advancements in the TDDS are transdermal patch design modification, incorporation of pressure sensitive adhesives and permeation enhancers that results in the enhancement of drug diffusion and increased the capacity to hold the drug in larger amount are expected to propel the demand for TDDS during the forecast period.Technological inventions such as the inclusion of microneedles or mechanical arrays in transdermal patches and miniaturized and advanced transdermal patches and reservoir type transdermal patches that deliver precise medication dose are expected to facilitate the market growth during the forecast period.Regional AnalysisThe Global Transdermal (Percutaneous) Drug Delivery Systems Market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
This is due to the existence of prominent market participants and developed healthcare infrastructure, a rising number of product launches and the continued participation of the leading vendors in conducting clinical trials in the US and Canada.Europe would be the second-largest value contributor in the transdermal (percutaneous) drug delivery systems market as the transdermal patches are gaining popularity in the UK, Germany, and France because patients and primary care physicians are mostly focused on easier drug delivery methods.The market in Asia-Pacific is forecasted to showcase comparatively higher CAGR during the forecast period attributed to growing older population base along with the rising prevalence of chronic diseases, growth in healthcare spending, raise in awareness about TDDS, and to increase research and development activities.The Middle East & Africa has the least share of the global transdermal drug delivery systems market.
Additionally, the major market share of the region would be held by the Middle East region due to growing healthcare sectors and health system reforms in the Gulf Cooperation Council (GCC) countries.Browse Complete Research Report @https://www.marketresearchfuture.com/reports/transdermal-drug-delivery-systems-market-7545Table Of Contents:Chapter 1.
Rise in geriatric population, increase in number of patients suffering from chronic disorders, increase in adoption of third-generation transdermal drug delivery systems, increased investments by the government and healthcare developments are key factors contributing to high CAGR of transdermal drug delivery system during forecast period.Market Size – USD 5.65 Billion in 2018, Market Growth - CAGR of 4.5%, Market Trends – Product launches and research for advanced transdermal drug delivery systemAccording to the current analysis of Reports and Data, the Transdermal Drug Delivery Systems market was valued at USD 5.65 Billion in 2018 and is anticipated to reach USD 8.03 Billion by the year 2026, at a CAGR of 4.5%.
These systems are an excellent alternative to the oral, intravascular, subcutaneous, and transmucosal routes, where medications are administered through the skin for therapeutic purposes.
By 2018, the pain management segment is expected to represent the majority of the market for transdermal drug delivery systems.
Dynamic distribution systems are classified into structure, electricity, and others.These drug delivery products are medicated adhesive patch that can be applied on the skin to give a specific dose of medication through the skin and into the blood.
An advantage of the transdermal drug delivery route is that the patch provides the patient with controlled release of the medicine, typically through a porous membrane overlying a reservoir of medication or body heat that melt thin adhesive medicine layers It is best to administer other types of medications, such as oral, topical, intravenous, intramuscular, etc.
Medication failures and withdrawals from transdermal drug delivery systems are also expected to limit market growth to some extent.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2272The report provides a complete analysis of the global Transdermal Drug Delivery Systems market with important details about the key market players from insightful primary and secondary research data.
The global Transdermal Drug Delivery Systems Market research study is an extensive collection of crucial information about the industry and offers an in-depth assessment of the business landscape.
The report also covers key statistical data of the market and sales statistics with the key data organized into tables, charts, diagrams, graphs, and other pictorial representations.
The report also covers overall scenario of the Transdermal Drug Delivery Systems market along with in-depth assessment of key market players, regional bifurcation, and key developments in the market.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2272The research report provides an in-depth analysis of the market over the forecast period along with assessment of current and future market trends.
It highlights key drivers, restraints, opportunities, limitations, and threats of the Transdermal Drug Delivery Systems market to offer key insights into the market and help readers and businesses formulate fruitful business strategies and investment plans.
The qualitative data gathered by extensive primary and secondary research presented in the report aims to provide crucial information regarding market dynamics, market trends, key developments and innovations, and product developments in the market.Major companies operating in the market and profiled in the report include:Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), and GlaxoSmithKline (UK).
It offers insights into segments expected to register significant growth over the forecast period and key factors and trends influencing revenue growth of the segment.Transdermal Drug Delivery Systems Market Segmentation:Type (Revenue, USD Million; 2016–2026)PatchesSemisolid formulationsOthersTechnology Type (Revenue, USD Million; 2016–2026)ThermalIontophoresisElectroporationUltrasoundElectric CurrentMicroporationMechanical ArraysRadio FrequencyApplications Type (Revenue, USD Million; 2016–2026)Pain Management,Central Nervous System Disorders,Hormonal Applications,Cardiovascular DiseasesEnd Use (Revenue, USD Million; 2016–2026)HospitalClinicOthersTo know more about the report @ https://www.reportsanddata.com/report-detail/transdermal-drug-delivery-systems-marketThe regional analysis of the global Transdermal Drug Delivery Systems market covers key geographical regions such as North America, Asia Pacific, Europe, Latin America, and Middle East & Africa.
The Transdermal Drug Delivery System Market 2021 research report gives emerging industry data, global segments and regional outlook.
This report covers up all details such as size, share, value, growth, restraints, and opportunities for the year 2020 to 2027.
The report generated using various analysis tools like porter’s five forces model, market attractiveness and value chain.
The report gives comprehensive review of the global market helping to club revenue generation and profitable business to transform client’s success.The report also covers detailed competitive landscape including company profiles of key players operating in the global market.
The key players in the transdermal drug delivery system market include 3M Company, 4P Therapeutics, LLC, Biogel Technology, Inc., BoehringerIngelheim GmbH, Echo Therapeutics, Inc., Johnson & Johnson, Mylan Pharmaceuticals, Inc., Novartis AG, Noven Pharmaceuticals, Inc., Skyepharma PLC, Transdermal Corp, Transdermal Technologies, Inc. and Watson Pharmaceuticals, Inc. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Get more information on "Global Transdermal Drug Delivery System Market Research Report" by requesting FREE Sample Copy athttps://www.valuemarketresearch.com/contact/transdermal-drug-delivery-system-market/download-sampleMarket DynamicsRising incidence of chronic diseases, with a growing interest in the development of novel drugs and delivering system, is driving the market growth.
Advantages such as longer drug effect, lesser side effects, painless drug delivery and low risk of infection transmission are further boosting the adoption of transdermal drug delivery system.
Transdermal Drug Delivery Systems: IntroductionTransdermal is a route of administration, wherein drugs are administered through the skin to achieve systemic distributionRecent advancements in transdermal route of administration such as ultrasound waves, laser, and microneedle patches for efficient penetration of the dermis layer of the skin drive the global transdermal drug delivery systems marketRequest Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=158 Key Drivers and Restraints of Global Transdermal Drug Delivery Systems MarketDemand for novel techniques with low dose and less dosing frequency of drugs is increasing rapidly.
Patients being discharged from health care services such as hospitals and clinics still need observation.
Hence, both professional caregivers and laypersons are using several types of equipment or devices, some of these composite, in non-institutional settings to control personal health, support others, or take support of health organization.
These equipment offer support in several health conditions such as chronic and acute diseases and help in prevention of diseases.Demand for automated drug delivery systems has increased.
For instance, Logiq wireless solutions is a remotely controlled transdermal drug delivery device.
These factors are projected to drive the global transdermal drug delivery systems market.Request COVID Analysis on Transdermal Drug Delivery Systems Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=158 Diabetes Application Segment to Lead Global MarketThe global transdermal drug delivery systems market can be segmented based on application, end-user, and regionIn terms of application, the global transdermal drug delivery systems market can be divided into infectious diseases, oncology, ophthalmology, urology, diabetes, CNS, and others.
The global Transdermal Drug Delivery Systems Market research study is an extensive collection of crucial information about the industry and offers an in-depth assessment of the business landscape.
The report also covers key statistical data of the market and sales statistics with the key data organized into tables, charts, diagrams, graphs, and other pictorial representations.
The report also covers overall scenario of the Transdermal Drug Delivery Systems market along with in-depth assessment of key market players, regional bifurcation, and key developments in the market.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2272The research report provides an in-depth analysis of the market over the forecast period along with assessment of current and future market trends.
It highlights key drivers, restraints, opportunities, limitations, and threats of the Transdermal Drug Delivery Systems market to offer key insights into the market and help readers and businesses formulate fruitful business strategies and investment plans.
The qualitative data gathered by extensive primary and secondary research presented in the report aims to provide crucial information regarding market dynamics, market trends, key developments and innovations, and product developments in the market.Major companies operating in the market and profiled in the report include:Hisamitsu Pharmaceutical (Japan), Mylan (US), UCB (Belgium), Novartis (Switzerland), and GlaxoSmithKline (UK).
It offers insights into segments expected to register significant growth over the forecast period and key factors and trends influencing revenue growth of the segment.Transdermal Drug Delivery Systems Market Segmentation:Type (Revenue, USD Million; 2016–2026)PatchesSemisolid formulationsOthersTechnology Type (Revenue, USD Million; 2016–2026)ThermalIontophoresisElectroporationUltrasoundElectric CurrentMicroporationMechanical ArraysRadio FrequencyApplications Type (Revenue, USD Million; 2016–2026)Pain Management,Central Nervous System Disorders,Hormonal Applications,Cardiovascular DiseasesEnd Use (Revenue, USD Million; 2016–2026)HospitalClinicOthersTo know more about the report @ https://www.reportsanddata.com/report-detail/transdermal-drug-delivery-systems-marketThe regional analysis of the global Transdermal Drug Delivery Systems market covers key geographical regions such as North America, Asia Pacific, Europe, Latin America, and Middle East & Africa.
The Transdermal Drug Delivery System Market 2021 research report gives emerging industry data, global segments and regional outlook.
This report covers up all details such as size, share, value, growth, restraints, and opportunities for the year 2020 to 2027.
The report generated using various analysis tools like porter’s five forces model, market attractiveness and value chain.
The report gives comprehensive review of the global market helping to club revenue generation and profitable business to transform client’s success.The report also covers detailed competitive landscape including company profiles of key players operating in the global market.
The key players in the transdermal drug delivery system market include 3M Company, 4P Therapeutics, LLC, Biogel Technology, Inc., BoehringerIngelheim GmbH, Echo Therapeutics, Inc., Johnson & Johnson, Mylan Pharmaceuticals, Inc., Novartis AG, Noven Pharmaceuticals, Inc., Skyepharma PLC, Transdermal Corp, Transdermal Technologies, Inc. and Watson Pharmaceuticals, Inc. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.Get more information on "Global Transdermal Drug Delivery System Market Research Report" by requesting FREE Sample Copy athttps://www.valuemarketresearch.com/contact/transdermal-drug-delivery-system-market/download-sampleMarket DynamicsRising incidence of chronic diseases, with a growing interest in the development of novel drugs and delivering system, is driving the market growth.
Advantages such as longer drug effect, lesser side effects, painless drug delivery and low risk of infection transmission are further boosting the adoption of transdermal drug delivery system.
The Global Transdermal (Percutaneous) Drug Delivery Systems Market Held A Market Value Of USD 5,400.2 Million In 2017 And Is Projected To Grow At A CAGR Of 4.6% Over The Forecast Period.Transdermal drug delivery system (TDDS) delivers drugs into systemic circulation into the skin through the skin at a predetermined rate with minimal inter and intrapatient variation.
For instance, as per the data published by the World Health Organization (WHO), in 2001, chronic diseases accounted for around 60.0% of the 56.5 million total reported deaths in the world and almost 46% of the global burden of disease.
By the end of 2020, chronic diseases are anticipated to contribute for nearly three-quarters of all deaths worldwide, and that 75% of deaths due to stroke, 71% of deaths due to ischemic heart disease (IHD), and 70% of deaths due to diabetes will occur in developing countries.Free sample report @ https://www.marketresearchfuture.com/sample_request/7545Key PlayersSome of the foremost players in the global transdermal (percutaneous) drug delivery systems market are Mylan N.V., Hisamitsu Pharmaceutical Co., Inc., Novartis International AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Endo Pharmaceuticals Inc., UCB S.A., Pfizer Inc., Allergan plc, Actelion Pharmaceuticals Ltd, and Noven Pharmaceuticals, Inc.SegmentationThe global transdermal (percutaneous) drug delivery systems market has been segmented into product, technology, application, and region.By product, the market has been segmented into transdermal patches and transdermal semisolids.
The transdermal semisolids segment is additionally divided into gels, ointments, and sprays.On the basis of technology, the market has been divided into electric current, iontophoresis, electroporation, ultrasound, microporation, thermal, and others.Based on application, the market has been categorized into pain management, cardiovascular diseases, hormone replacement therapy, central nervous system disorders, smoking cessation, contraception, and others.Few of the technological advancements in the TDDS are transdermal patch design modification, incorporation of pressure sensitive adhesives and permeation enhancers that results in the enhancement of drug diffusion and increased the capacity to hold the drug in larger amount are expected to propel the demand for TDDS during the forecast period.Technological inventions such as the inclusion of microneedles or mechanical arrays in transdermal patches and miniaturized and advanced transdermal patches and reservoir type transdermal patches that deliver precise medication dose are expected to facilitate the market growth during the forecast period.Regional AnalysisThe Global Transdermal (Percutaneous) Drug Delivery Systems Market has been segmented by region into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
This is due to the existence of prominent market participants and developed healthcare infrastructure, a rising number of product launches and the continued participation of the leading vendors in conducting clinical trials in the US and Canada.Europe would be the second-largest value contributor in the transdermal (percutaneous) drug delivery systems market as the transdermal patches are gaining popularity in the UK, Germany, and France because patients and primary care physicians are mostly focused on easier drug delivery methods.The market in Asia-Pacific is forecasted to showcase comparatively higher CAGR during the forecast period attributed to growing older population base along with the rising prevalence of chronic diseases, growth in healthcare spending, raise in awareness about TDDS, and to increase research and development activities.The Middle East & Africa has the least share of the global transdermal drug delivery systems market.
Additionally, the major market share of the region would be held by the Middle East region due to growing healthcare sectors and health system reforms in the Gulf Cooperation Council (GCC) countries.Browse Complete Research Report @https://www.marketresearchfuture.com/reports/transdermal-drug-delivery-systems-market-7545Table Of Contents:Chapter 1.
Rise in geriatric population, increase in number of patients suffering from chronic disorders, increase in adoption of third-generation transdermal drug delivery systems, increased investments by the government and healthcare developments are key factors contributing to high CAGR of transdermal drug delivery system during forecast period.Market Size – USD 5.65 Billion in 2018, Market Growth - CAGR of 4.5%, Market Trends – Product launches and research for advanced transdermal drug delivery systemAccording to the current analysis of Reports and Data, the Transdermal Drug Delivery Systems market was valued at USD 5.65 Billion in 2018 and is anticipated to reach USD 8.03 Billion by the year 2026, at a CAGR of 4.5%.
These systems are an excellent alternative to the oral, intravascular, subcutaneous, and transmucosal routes, where medications are administered through the skin for therapeutic purposes.
By 2018, the pain management segment is expected to represent the majority of the market for transdermal drug delivery systems.
Dynamic distribution systems are classified into structure, electricity, and others.These drug delivery products are medicated adhesive patch that can be applied on the skin to give a specific dose of medication through the skin and into the blood.
An advantage of the transdermal drug delivery route is that the patch provides the patient with controlled release of the medicine, typically through a porous membrane overlying a reservoir of medication or body heat that melt thin adhesive medicine layers It is best to administer other types of medications, such as oral, topical, intravenous, intramuscular, etc.
Medication failures and withdrawals from transdermal drug delivery systems are also expected to limit market growth to some extent.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2272The report provides a complete analysis of the global Transdermal Drug Delivery Systems market with important details about the key market players from insightful primary and secondary research data.